Filament Health delivers PEX010 for Phase 3 microdose psilocybin trial

Rhelion Life Sciences says its wholly owned subsidiary Filament Health delivered PEX010 to Bruyere Health Research Institute for its Phase 3 trial of microdose psilocybin in palliative care.